Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 882 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Period C Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Nitrate and Vitamin C on Vascular Health Oxidative Stress

NCT04283630
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Dietary nitrate in the form of beetroot juice for all participnats, Nature Made vitamin c 1000 mg, Placebo
Dietary Supplement
Lead sponsor
David Travis Thomas
Other
Eligibility
50 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 31, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study To Characterize The Pharmacokinetics And The Effects Of Food On Oxycodone In Healthy Volunteers

NCT01530542
View directory record Official record
Conditions
Analgesia, Acute Pain, Chronic Pain, Narcotic Abuse, Opioid-related Disorders
Interventions
oxycodone hydrochloride, marketed oxycodone hydrochloride
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2012 · Synced Oct 31, 2026, 5:40 AM EDT
Active, not recruiting Not applicable Interventional

Assessment of Combined CCM and ICD Device in HFrEF

NCT05855135
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction, Implantable Defibrillator User, CCM Therapy, Non-ischemic Cardiomyopathy, Ischemic Cardiomyopathy, Sudden Cardiac Arrest, Arrhythmias, Cardiac, Ventricular Tachycardia, Ventricular Fibrillation
Interventions
OPTIMIZER® Integra CCM-D System (Treatment Arm)
Device
Lead sponsor
Impulse Dynamics
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
59
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 31, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Bioavailability of Naloxone Nasal Spray, Naloxone Hydrochloride (HCl) Intravenous (IV) and Intramuscular Injection (IM) in Healthy Volunteers

NCT03827642
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Treatment A: Naloxone Nasal Spray, Treatment B: Naloxone Nasal Spray, Treatment C: Naloxone HCl Intravenous (IV) Injection, Treatment D: Naloxone HCl Intramuscular (IM) Injection
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 31, 2026, 5:40 AM EDT
Completed Phase 1 Interventional

Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study

NCT01956305
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
DS-7309, placebo, Metformin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 31, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule

NCT02382640
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Febuxostat XR, Maalox Advance Regular Strength liquid
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2016 · Synced Oct 31, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

NCT02453022
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet, Prilosec (omeprazole) 40mg Delayed-Release capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 31, 2026, 5:40 AM EDT
Recruiting Not applicable Interventional

Bio Leg: Advancing Mobility (BAM)

NCT07613502
View directory record Official record
Conditions
Amputation of Lower Limb Above Knee, Amputee, Amputation
Interventions
Bio Leg
Device
Lead sponsor
University of Florida
Other
Eligibility
40 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 5:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparative Bioavailability of Dronabinol Oral Solution in Healthy Volunteers

NCT02604992
View directory record Official record
Conditions
Healthy
Interventions
Treatment A, Treatment B, Treatment C
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 31, 2026, 5:40 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

NCT03131206
View directory record Official record
Conditions
ALK-positive Non-small Cell Lung Cancer (NSCLC), RET-positive Non-small Cell Lung Cancer (NSCLC), RET-positive Thyroid Cancer
Interventions
Alectinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Irvine, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Oct 31, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability For Palbociclib Formulations

NCT02083640
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib Formulation Reference, Palbociclib Formulation Test
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 31, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect

NCT01072162
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
Eltrombopag
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 31, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects

NCT01114607
View directory record Official record
Conditions
Crohn's Disease
Interventions
GSK1605786 ChemoCentryx: formulation A, GSK1605786 GSK: formulation B, GSK1605786 GSK direct-fill: formulation C, GSK1605786 GSK modified-process: formulation D, GSK1605786 GSK tablet: formulation E
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 31, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

NCT03751657
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Placebo (insulin 287), Metformin, Dipeptidyl peptidase-4 inhibitors, Insulin glargine, Placebo (insulin glargine)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Lancaster, California • Ventura, California • Walnut Creek, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 31, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

NCT04394351
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Dupilumab, Matching Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Year to 11 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 31, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants

NCT07020988
View directory record Official record
Conditions
Healthy Participants
Interventions
Staccato Alprazolam, Midazolam, Diazepam
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
20 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 31, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SAD Study of IA-14069

NCT05317741
View directory record Official record
Conditions
Healthy
Interventions
IA-14069, Placebo
Drug
Lead sponsor
ILAb Co., Ltd.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 31, 2026, 5:40 AM EDT
Active, not recruiting Phase 2 Interventional

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT02427620
View directory record Official record
Conditions
Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Doxorubicin Hydrochloride, Ibrutinib, Laboratory Biomarker Analysis, Methotrexate, Rituximab, Vincristine, Vincristine Sulfate
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 31, 2026, 5:40 AM EDT
Active, not recruiting Phase 3 Interventional

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

NCT04759586
View directory record Official record
Conditions
Primary Mediastinal Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, Filgrastim, Lumbar Puncture, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Prednisolone, Prednisone, Radiation Therapy, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
215
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 162 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 31, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers

NCT06137703
View directory record Official record
Conditions
Biological Availability
Interventions
Zavegepant 100mg non-enteric coated soft gel capsule, Zavegepant 100mg immediate release tablet, Zavegepant 2 x 100mg immediate release tablets, Zavegepant 4 x 25mg enteric coated soft gel capsule
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 31, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults

NCT05349864
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-07284890 Treatment A, PF-07284890 Treatment B, PF-07284890 Treatment C
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 31, 2026, 5:40 AM EDT
Recruiting Early Phase 1 Interventional

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

NCT05651828
View directory record Official record
Conditions
Advanced Basal Cell Carcinoma
Interventions
Vismodegib 150 MG Oral Capsule
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 31, 2026, 5:40 AM EDT
Completed Phase 1 Interventional

Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

NCT04006704
View directory record Official record
Conditions
HIV-1
Interventions
D/C/F/TAF FDC placebo
Drug
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
6 Years to 11 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Phoenix, Arizona • Atlanta, Georgia • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 31, 2026, 5:40 AM EDT
Completed Phase 2 Interventional

Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa

NCT02695212
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Apremilast
Drug
Lead sponsor
Florida Academic Dermatology Centers
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 31, 2026, 5:40 AM EDT